(Q38170457)

30 August 2017

Application of genotype-guided cancer therapy in solid tumors (English)

1 reference

30 August 2017

Jai N Patel

1

1 reference

30 August 2017

1 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

15

1 reference

30 August 2017

1

1 reference

30 August 2017

79-93

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

30 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Part 1: background, methodology, and clinical adoption of pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Genotype-guided tamoxifen therapy: time to pause for reflection?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Orally administered endoxifen is a new therapeutic agent for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Pharmacogenetics and stomach cancer: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Should DPD analysis be required prior to prescribing fluoropyrimidines?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Gastric cancer pharmacogenetics: progress or old tripe?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Future of personalized medicine in oncology: a systems biology approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Genotyping technologies for genetic research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Multiplicity: an organizing principle for cancers and somatic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Ethical and social issues in pharmacogenomics testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Pharmacogenetics: the ethical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

21 January 2018

Is GINA worth the wait?

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Genomics, health care, and society

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Cancer pharmacogenomics: early promise, but concerted effort needed

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Economic opportunities and challenges for pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

DPYD*2A mutation: the most common mutation associated with DPD deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

FDA drug approval summary: erlotinib (Tarceva) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

Prevalence of ras gene mutations in human colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.227

21 January 2018

Identifiers

DOI

10.2217/PGS.13.227

1 reference

30 August 2017

1 reference

PubMed ID

24329193